These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38086013)

  • 1. Prior Authorization and Association With Delayed or Discontinued Prescription Fills.
    Kyle MA; Keating NL
    J Clin Oncol; 2024 Mar; 42(8):951-960. PubMed ID: 38086013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries.
    Mark TL; Parish WJ; Zarkin GA
    JAMA Netw Open; 2020 Apr; 3(4):e203132. PubMed ID: 32310285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Multichannel Medication Adherence Intervention Influences Patient and Prescriber Behavior.
    Leslie RS; Gilmer T; Natarajan L; Hovell M
    J Manag Care Spec Pharm; 2016 May; 22(5):526-38. PubMed ID: 27123914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
    Parish WJ; Mark TL; Zarkin GA; Weber E
    Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization Management in the Medicare Part D Program and Prescription Drug Utilization.
    Andersen MS
    Forum Health Econ Policy; 2021 Jun; 24(1):1-34. PubMed ID: 36194915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Prior Authorization in Medicare Nonemergent Ambulance Transport.
    Contreary K; Asher A; Coopersmith J
    JAMA Health Forum; 2022 Jul; 3(7):e222093. PubMed ID: 35977218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal of prior authorization for medication-assisted treatment: impact on opioid use and policy implications in a Medicare Advantage population.
    Ferries E; Racsa P; Bizzell B; Rhodes C; Suehs B
    J Manag Care Spec Pharm; 2021 May; 27(5):596-606. PubMed ID: 33908274
    [No Abstract]   [Full Text] [Related]  

  • 8. Association between dispensing channel and medication adherence among medicare beneficiaries taking medications to treat diabetes, high blood pressure, or high blood cholesterol.
    Iyengar RN; Balagere DS; Henderson RR; LeFrancois AL; Rabbitt RM; Frazee SG
    J Manag Care Spec Pharm; 2014 Aug; 20(8):851-61. PubMed ID: 25062079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction.
    Ozaki AF; Krumholz HM; Mody FV; Tran TT; Le QT; Yokota M; Jackevicius CA
    Circ Cardiovasc Qual Outcomes; 2021 Sep; 14(9):e007665. PubMed ID: 34465124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a high dosage opioid prior authorization policy on prescription opioid use, misuse, and overdose outcomes.
    Hartung DM; Kim H; Ahmed SM; Middleton L; Keast S; Deyo RA; Zhang K; McConnell KJ
    Subst Abus; 2018; 39(2):239-246. PubMed ID: 29016245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring the Scope of Prior Authorization Policies: Applying Private Insurer Rules to Medicare Part B.
    Schwartz AL; Brennan TA; Verbrugge DJ; Newhouse JP
    JAMA Health Forum; 2021 May; 2(5):e210859. PubMed ID: 35977311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.
    Law MR; Lu CY; Soumerai SB; Graves AJ; LeCates RF; Zhang F; Ross-Degnan D; Adams AS
    Clin Ther; 2010 Apr; 32(4):729-41; discussion 716. PubMed ID: 20435243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.
    Linton A; Bacon T; Peterson M
    J Manag Care Pharm; 2009; 15(1):42-54. PubMed ID: 19125549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries.
    Doshi JA; Jahnke J; Raman S; Puckett JT; Brown VT; Ward MA; Li P; Manz CR
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1457-1468. PubMed ID: 34595957
    [No Abstract]   [Full Text] [Related]  

  • 17. Association Between Copayment Assistance, Insurance Type, Prior Authorization, and Time to Receipt of Oral Anticancer Drugs.
    Lichtenstein MRL; Beauchemin MP; Raghunathan R; Lee S; Doshi SD; Law C; Accordino MK; Elkin EB; Wright JD; Hershman DL
    JCO Oncol Pract; 2024 Jan; 20(1):85-92. PubMed ID: 38033273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions.
    Doshi JA; Li P; Puckett JT; Pettit AR; Raman S; Parmacek MS; Rader DJ
    Value Health; 2020 Feb; 23(2):209-216. PubMed ID: 32113626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
    Pauly NJ; Talbert JC; Brown J
    J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.
    Jung K; McBean AM; Kim JA
    J Manag Care Pharm; 2012 Mar; 18(2):106-15. PubMed ID: 22380470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.